Questions Over Adjuvant Ipilimumab in Melanoma

An editorial raises questions on data for patient-reported outcomes for adjuvant ipilimumab, 10 mg/kg, in melanoma; toxicity also questioned.
Medscape Medical News

http://ift.tt/2lXtygX